GLP-1 receptor agonists: differentiation within the class
نویسندگان
چکیده
منابع مشابه
The Cardiovascular Effects of GLP-1 Receptor Agonists
Glucagon-like peptide-1 receptor (GLP-1R) agonists have been shown to regulate blood glucose concentrations by mechanisms including enhanced insulin synthesis/secretion, suppressed glucagon secretion, slowed gastric emptying, and enhanced satiety. GLP-1 receptors have also been identified in the heart, kidneys, and blood vessels, leading to the hypothesis that GLP-1R agonists may affect cardiov...
متن کاملDifferentiating between GLP-1 receptor agonists and DPP-4 inhibitors
Article points 1. Dipeptidyl peptidase-4 inhibitors (DPP-4Is) inhibit the activity of DPP-4 to prolong the effects of native glucagon-like peptide-1 (GLP-1), whereas GLP-1 receptor agonists (GLP-1RAs) provide activation of the GLP-1 receptor while remaining resistant to degradation by DPP-4. 2. Both DPP-4Is and GLP-1RAs provide glycaemic control in people with type 2 diabetes, and GLP-1RAs are ...
متن کاملGLP-1 receptor agonists and heart failure in diabetes.
The prevalence of heart failure (HF) is increasing in patients with type 2 diabetes (T2D), and glucose-lowering agents have distinctive effects on the risk of developing HF that requires hospitalization. Such an increased risk has been consistently reported with thiazolidinediones (glitazones) and perhaps also with the dipeptidyl peptidase (DPP)-4 inhibitor saxagliptin (at least in SAVOR - TIMI...
متن کاملBasal Insulin Use With GLP-1 Receptor Agonists
IN BRIEF The combination of basal insulin and a glucagon-like peptide 1 receptor agonist is becoming increasingly common and offers several potential benefits to patients with type 2 diabetes. Clinical studies have demonstrated improved glycemic control and low risks of hypoglycemia and weight gain with the combination, which provides a safe and effective alternative to basal-bolus insulin with...
متن کاملDrugs for diabetes : part 6 GLP - 1 receptor agonists
Br J Cardiol 2011;18:167−9 T glucagon-like peptide-1 (GLP-1) receptor agonists are a new class of injected drugs for the treatment of type 2 diabetes. They mimic the action of GLP-1 and increase the incretin effect in patients with type 2 diabetes, stimulating the release of insulin. They have additional effects in reducing glucagon, slowing gastric emptying, and inducing satiety. In clinical p...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Lancet Diabetes & Endocrinology
سال: 2018
ISSN: 2213-8587
DOI: 10.1016/s2213-8587(17)30413-8